Save the date for the virtual event Rethinking Alzheimer’s disease: Moving towards a new Alzheimer’s disease detection and diagnosis pathway in Sweden, set to take place on 26 September 2023 at 10:00 – 12:00 (Brussels time)!
About Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur. It is the underlying cause in 70% of people with dementia. Dementia, which is not a specific disease but an overall term that describes a group of symptoms, is characterised by a decline in memory, thinking, behaviour and the ability to perform everyday activities.
It is estimated that 7 million people in Europe alone already live with Alzheimer’s disease and dementia. With a rapidly ageing population, it is a growing public health concern worldwide as this number is projected to rise to a staggering 14 million by 2030.
Rethinking Alzheimer’s disease: Moving towards a new Alzheimer’s disease detection and diagnosis pathway in Sweden
The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Swedish Brain Foundation (SBF) and the Swedish Association of the Pharmaceutical Industry (LIF), will explore the ways we can rethink the Alzheimer’s care pathway, particularly in the Swedish healthcare context.
The virtual event follows the launch of the Rethinking Alzheimer’s Disease White Paper: Detection & Diagnosis, looking at how to detect and diagnose the disease at an earlier stage (at mild cognitive impairment – MCI – stage) and what new care pathways would need to be implemented to reach out to patients at that stage. Furthermore, with disease modifying treatments targeting patients with MCI potentially coming to market in the near future, it is important to see how prepared healthcare systems are to provide these new treatments.
The programme will feature keynote speeches on daily life living with Alzheimer’s disease and how we can rethink the Alzheimer’s care pathway, a panel discussion featuring key opinion leaders and experts involved in the Rethinking Alzheimer’s disease project, and much more. Follow the EBC social media channels (Twitter, LinkedIn) and dedicated newsletter for all the latest updates – more information coming soon!